Ischemic stroke in young adults is a well-known disease, but despite extensive clinical and laboratory investigations, its etiology remains unclear in approximately half of the cases. We examined the prevalence of factor V Leiden, the prothrombin G20210A genotype, and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in 100 patients (51 males and 49 females) who survived an ischemic stroke without a cardiac embolic source at an age ≤45 years, and in 238 healthy control subjects from the same geographic area. The patients were selected for study only if the diagnosis of stroke was documented by computed tomography scan or nuclear magnetic resonance (NMR) of the brain, or both. Heterozygosity for the FV Leiden mutation was found in 3 patients (3.0%) and in 10 control subjects (4.2%). Two patients (2.0%) and five control subjects (2.1%) were heterozygous for the prothrombin G20210A mutation. The frequencies of the MTHFR 677TT, CT, and CC genotypes in the patient group were 12%, 37%, and 51%, respectively, and were not significantly different from those in control subjects (11%, 40%, and 49%, respectively). In conclusion, our results indicate that FV Leiden mutation, prothrombin G20210A genotype, and homozygosity for the C677T mutation in the MTHFR gene are not associated with an increased risk for ischemic stroke in young adults.
Bertina RMMolecular risk factors for thrombosis. Thromb Haemost1999;82:601.
2.
Bertina RMKoelman BP, Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature1994;369:64.
3.
Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3' untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood1966;88:3698.
4.
Ridker PM, Hennekens CH, Lindpaintner K., et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med1995;332:912.
5.
Ridker PM, Hennekens CH, Miletich JPG20210A mutation in the prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation1999: 99:999.
6.
Nehler MR, Taylor LM, Porter JMHomocysteinemia as a risk factor for atherosclerosis: a review. Cardiovasc Pathol1997;6:1.
7.
Frosst P., Blom HJ, Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet1995;10:111.
8.
Adams HPBendixen BHKappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke1993;24:35.
9.
Miller SA, Dykes DD, Polesky HFA simple salting out procedure for extracting DNA from human nucleated cells . Nucleic Acids Res1988;16:1215.
10.
Blecic S. Bogousslavsky J.Stroke in young adults. In: Barnett HJM, Mohr JP, Stein BM, et al, eds. Stroke: Pathophysiology, Diagnosis, and Management. New York: Churchill Livingstone, 1998:1001.
11.
Matsushita K., Kuriyama Y., Sawada T., et al. Cerebral infarction associated with protein C deficiency. Stroke1992;23:108.
12.
Martinez HR , Rangel-Guerra RA, Marfil LJIschemic stroke due to deficiency of coagulation inhibitors: report of 10 young adults. Stroke1993;24:19.
13.
Lalouschek W., Aull S., Series W., et al. C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. Thromb Res1999;93:61.
14.
Catto A., Carter A., Ireland H., et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol1995;15:783.
15.
Press RD, Liu XYBeamer N., et al. Ischemic Stroke in the elderly. Role of common factor V mutation causing resistance to activated protein C. Stroke1996;27:44.
16.
Landi G., Cella E., Martinelli I., et al. Arg506GIn factor V mutation and cerebral ischemia in the young . Stroke1966;27:1697.
17.
Genasan V., Kelsey H., Cookson J., et al. Activated protein C resistance in childhood stroke. Lancet1996;347:260.
18.
Nowak-Göttel U., Sträter R., Dübbers A., et al. Ischemic stroke in infancy and childhood: role of the Arg 506 to Gln mutation in the factor V gene. Blood Coagul Fibrinolysis1996;7:684.
19.
Albucher JF , Guiraud-Chumeil B., Chollet F., et al. Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke . Stroke1996;27:766.
20.
Thorarensen O.Ryan S., Hunter J., et al. Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis . Ann Neurol1997;42:372.
21.
Nabavi DG, Junker R., Wolff E., et al. Prevalence of factor V Leiden mutation in young adults with cerebral ischemia: a case-control study on 225 patients. J Neurol1988;245:653.
22.
Zenz W., Bodo Z., Plotho J., et al. Factor V Leiden and prothrombin gene G20210A variant in children with ischemic stroke. Thromb Haemost1998;80:763.
23.
Margaglione M., D'Andrea G., Giuliani N., et al. Inherited prothrombotic conditions and premature ischemic stroke. Sex difference in the association with factor V Leiden. Arterioscler Thromb Vasc Biol1999 ;19:1751.
24.
Riikonen RS , Vahtera EM, Kekomaki RMPhysiological anticoagulants and activated protein C resistance in childhood stroke. Acta Paediatr1996;85:242.
25.
McColl MD, Chalmers EA, Thomas A., et al. Factor V Leiden, prothrombin 20210G→A and MTHFR C677T mutations in childhood stroke. Thromb Haemost1999;81:690.
26.
De Stefano V., Chiusolo P., Paciaroni K., et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood1998,91:3562.
27.
Becker S., Heller C., Gropp F., et al. Thrombophilic disorders in children with cerebral infarction . Lancet1998;352:1756.
28.
Arruda VR, von Zuben PM, Chiaparini LC, et at. The mutation Ala677→Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost1997;77:818.
29.
Morita H., Kurichara H., Tsubaki S. et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vase Biol1998:18:1465.
30.
Reuner KH, Ruf A., Kaps M., et al. The mutation Ch77→T in the methylene tetrahydrofolate reductase gene and stroke. Thromb Haemost1998;79:450.
31.
Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentration. Circulation1996;93:7.
32.
Spence JDMalinow MR, Barnett PA, et al. Plasma homocyst-(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. Stroke1999;30:969.
33.
Brattström L.Wilcken Del.Ohrvik J., et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of meta-analysis. Circulation1998;98:2520.
34.
Brown K., Luddington R., Baglin T.Effect of the MTHFR C677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol1998;103:42.
35.
Bonita R.Epidemiology of stroke. Lancet1992 :339:342.
36.
Kristensen SR, Andersen-Ranberg K.Bathum L. et al. Factor V Leiden and venous thrombosis in Danish centenarians. Thromb Haemost1998;80:860.
37.
Sacchi E., Duca F., Franceschi C., et al. Prothrombin gene mutation (G20210A) in healthy centenarians . Thromb Haemost1999,81: 990.
38.
Rees DC, Cox M., Clegg JBWorld distribution of factor V Leiden. Lancet1995;346:1133.
39.
Herrmann FH , Koesling M. Schröder W, et al. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol1997; 14:403.
40.
Rosendaal FR , Doggen Cjm, Zivelin A., et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost1998;79:706.
41.
Franco RF, Araújo AGGuerriero JF, et al. Analysis of the 677 C→T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost1998;79:119.
